Shots: GI Innovations to receive $17M upfront, $1.2B as development & commercialization milestones along with royalties on sales of therapy Yuhan to get global rights (Ex-Japan) to develop and commercialize GI-301 while collaborates with GI Innovations for the development of therapy As per collaboration, the companies will develop allergy treatment across all four major allergic […]Read More
Shots: GI to receive up front, milestones, and royalties on sales in China, including mainland China, Hong Kong, Macau, and Taiwan while Simcere will be responsible for all clinical development, regulatory approval and commercialization of the assets in territories The focus of the collaboration is to develop monotherapy as well as combination therapy with immune […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
